Lokelma (sodium zirconium cyclosilicate)
- Region
- 🇪🇺 EU
- Active substance
- sodium zirconium cyclosilicate
- Company
- AstraZeneca AB
- Status
- Authorised
- Therapeutic area
- Hyperkalemia
- CHMP opinion
- Thu 26 Jan 2017
- EU approval
- Thu 22 Mar 2018
- Application
- EMEA/H/C/004029
- ATC
- V03AE10
- Official record
- www.ema.europa.eu
Indication
Lokelma is indicated for the treatment of hyperkalaemia in adult patients.
Regulatory milestones
No milestones recorded in the last year.
Follow Lokelma
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.